Today: 7 February 2026
Subscribe
Browse Category

Financial Results News 9 November 2025 - 16 November 2025

NAB (ASX:NAB) pre‑open on 17 Nov 2025: Dividend timetable, $1.75bn notes, FY25 takeaways and the RBA backdrop

NAB (ASX:NAB) pre‑open on 17 Nov 2025: Dividend timetable, $1.75bn notes, FY25 takeaways and the RBA backdrop

Here’s everything investors need to know about National Australia Bank before the ASX opens on Monday, 17 November 2025 (AEDT). Quick take Where NAB shares finished last week NAB shares settled at A$41.48 on Friday, 14 November—down 1.71% on the session. Versus the previous Friday’s A$43.44 close, the stock is roughly 4.5% lower week‑on‑week, reflecting a soft patch for the big banks after results and macro headlines. Yahoo Finance+1 FY25 at a glance: what the bank just told the market On 6 November, NAB reported FY25 cash earnings of A$7.091bn (‑0.2% YoY) and statutory net profit of A$6.759bn. The net
16 November 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the $920–$970B range, reflecting price swings and share count. On trailing metrics the stock trades near 50x earnings; on Lilly’s 2025 EPS guide midpoint (~$23.35), the forward P/E is ~44x. That premium embeds continued GLP‑1 scale‑up and pipeline options. Lightyear What changed in November 2025 Q3 2025: the numbers behind the momentum Therapeutic expansions that matter for the model Valuation check
15 November 2025
····
Milestone Scientific (MLSS) Soars on Q3 2025 Earnings, Cost Cuts and Board Shake-Up – Latest for 14 November 2025

Milestone Scientific (MLSS) Soars on Q3 2025 Earnings, Cost Cuts and Board Shake-Up – Latest for 14 November 2025

Milestone Scientific Inc. (NYSE American: MLSS) is back on traders’ radar today after a sharp after‑hours spike, strong pre‑market performance and fresh Q3 2025 numbers that show progress on costs but lingering listing‑compliance and funding risks. Key headlines on Milestone Scientific today As of Friday, 14 November 2025, these are the main developments around Milestone Scientific: MLSS stock today: big moves, tiny price According to real‑time quote data, Milestone Scientific shares are changing hands around $0.37 this afternoon, down slightly on the day but still well above where they traded before the earnings release. Intraday, the stock has: Recent performance
14 November 2025
····
Siemens Energy Hits Record Highs as Analysts Boost Targets: How AI, Grid Demand and a Wind Turnaround Drive the Stock Rally

Siemens Energy Shares Soar as Record Profit, Dividend Comeback and Higher 2028 Targets Mark End of Crisis

Munich/Berlin – 14 November 2025 – Siemens Energy has drawn a bold line under its crisis years. The German energy technology group has reported the highest profit in its history, sharply raised its medium‑term financial targets, announced its first dividend in four years – and watched its share price rocket towards a record high. Behind the headlines is a story of surging global electricity demand, AI‑driven data centre expansion, a booming grid and gas business – and a still‑troubled wind division that management insists it can fix. Record €1.7 Billion Profit Signals a Turnaround For the financial year 2025 (October 2024
14 November 2025
·····
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

CYPH Debuts: Cypherpunk Technologies (ex‑Leap Therapeutics) starts trading, files $200M ATM, posts Q3 results and details $50M Zcash treasury — 13 Nov 2025

Published: November 13, 2025 Cypherpunk Technologies Inc. — the newly renamed Leap Therapeutics — began trading on the Nasdaq this morning under the ticker CYPH, marking the company’s formal pivot from oncology biotech to a “digital‑asset treasury” strategy centered on Zcash (ZEC). Options symbols and identifiers also updated in step with the change. PR Newswire+1 What changed today The strategy pivot: from Leap Therapeutics to Cypherpunk The company has rebranded to Cypherpunk Technologies Inc. and disclosed a $50 million initial purchase of 203,775.27 ZEC (Zcash’s native coin) at a $245.37 average cost using proceeds from its October private placement led
13 November 2025
···
Tata Capital’s ₹15,500-Crore IPO Rocks 2025 Markets – Should You Bet on India’s Biggest Listing?

Tata Motors Commercial Vehicles (TMCV) Share Price Today, 13 November 2025: Profit‑Taking, Q2 Buzz and What It Means for Investors

Tata Motors’ newly listed commercial vehicles arm is having a busy second day on the bourses. On Thursday, 13 November 2025, Tata Motors Ltd (commercial vehicles business, ticker: TMCV) traded lower as investors booked profits ahead of the company’s first standalone quarterly results post demerger. 1. TMCV share price today: how the stock traded According to exchange data compiled by Economic Times and Upstox, Tata Motors Commercial Vehicles (TMCV): Business Standard’s and ET’s data also indicate that the stock has quickly moved from a fresh high near ₹345 on listing day to testing new lows around ₹315–316, effectively setting a
13 November 2025
····
CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix Inc. (NASDAQ: CRMD) reported a profitable third quarter and lifted full‑year guidance today as momentum in DefenCath and contributions from the Melinta portfolio accelerated growth. TradingView What happened CorMedix said third‑quarter 2025 net revenue came in at $104.3 million (pro forma $130.8 million), fueled by higher‑than‑expected outpatient DefenCath utilization and partial‑quarter sales from the Melinta portfolio. The company posted net income of $108.6 million and Adjusted EBITDA of $71.9 million for the period. Management raised full‑year 2025 pro forma net revenue guidance to $390–$410 million and set Q4 net revenue guidance at $115–$135 million, while lifting fully synergized pro
12 November 2025
···
Jumia (JMIA) Q3 2025: Revenue +25%, GMV +21%, Orders Surge; FY‑2025 Loss Guided to $50–55M, Q4’26 Breakeven Target

Jumia (JMIA) Q3 2025: Revenue +25%, GMV +21%, Orders Surge; FY‑2025 Loss Guided to $50–55M, Q4’26 Breakeven Target

Jumia Technologies AG (NYSE: JMIA) reported third‑quarter 2025 results before the U.S. market open today, showing accelerating top‑line growth and improving operating metrics while refining its 2025 loss outlook and reiterating a path to profitability. The Africa‑focused ecommerce group also confirmed tomorrow’s Investor Day and an earnings call at 8:30 a.m. ET today. SEC+1 Key numbers (Q3 2025, year over year) Usage momentum (physical goods, perimeter‑adjusted): Context on mix: As part of its shift away from low‑value digital orders, JumiaPay app orders fell sharply year over year, a deliberate pivot that lifted physical‑goods engagement metrics. SEC Guidance & profitability roadmap
12 November 2025
···
Infineon Lifts 2026 AI Power Revenue Target to €1.5bn as FY 2025 Lands in Line—Stock Jumps on DAX (12 November 2025)

Infineon Lifts 2026 AI Power Revenue Target to €1.5bn as FY 2025 Lands in Line—Stock Jumps on DAX (12 November 2025)

Munich — 12 November 2025. German chipmaker Infineon Technologies is leaning harder into the artificial‑intelligence build‑out. After reporting full‑year results broadly in line with guidance, the company sharply raised its 2026 sales goal for power‑supply solutions used in AI data centers—a move that sent the shares higher in Frankfurt trading. FT Markets+1 Why it matters Results at a glance (FY 2025; year ended 30 September) For the just‑ended Q4 FY 2025, revenue was €3.943 billion and the Segment Result reached €717 million (18.2% margin). FT Markets AI data centers are the growth engine Infineon’s business supplying power semiconductors and system solutions for AI servers accelerated markedly this year. The company generated more than
12 November 2025
····
ZenaTech (ZENA) Q3: Revenue Jumps 1,225% as Drone‑as‑a‑Service Scales — All the News Today (Nov. 11, 2025)

ZenaTech (ZENA) Q3: Revenue Jumps 1,225% as Drone‑as‑a‑Service Scales — All the News Today (Nov. 11, 2025)

ZenaTech, Inc. (NASDAQ: ZENA; FSE: 49Q; BMV: ZENA) reported record third‑quarter results this morning, led by a surge in Drone‑as‑a‑Service (DaaS) revenue and continued expansion via acquisitions. Financial outlets picked up the release across the day, while filings show the company furnished unaudited nine‑month financials to the SEC. Here’s everything published today, Nov. 11, 2025, plus what it means for the stock and the drone services market. GlobeNewswire What ZenaTech announced today How markets and media reacted today (Nov. 11) Stock action at a glance As of early afternoon (approx. 14:39 UTC), ZENA traded around $4.01, with an intraday range
11 November 2025
···
Bajaj Finserv Q2 FY26: Net Profit Rises to ₹2,244 Crore; Bajaj Finance Cuts FY26 AUM Guidance to 22–23% as Credit Costs Stay Elevated (11 Nov 2025)

Bajaj Finserv Q2 FY26: Net Profit Rises to ₹2,244 Crore; Bajaj Finance Cuts FY26 AUM Guidance to 22–23% as Credit Costs Stay Elevated (11 Nov 2025)

Dateline: Mumbai | November 11, 2025 Summary: Bajaj Finserv reported a steady September-quarter profit, while flagship lender Bajaj Finance delivered robust growth but trimmed its FY26 asset‑growth outlook, triggering a sharp sell‑off in both counters on Tuesday. Bajaj Finserv Q2 FY26: Profit holds up; revenue grows 11% Bajaj Finserv reported net profit of ₹2,244 crore for Q2 FY26 with revenue from operations up 11% to ₹37,403 crore. On a consolidated basis, profit rose ~7.5% year‑on‑year, while on a standalone basis the rise was 23.9%, aided by higher dividend income from lending and insurance subsidiaries. Management also highlighted steady underlying operating
11 November 2025
··
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. Bristol Myers Squibb News Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding
9 November 2025
····
1 … 10 11 12 13 14

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop